MRI Study of Blood-brain Barrier Function in CADASIL

Sponsor
Peking University First Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05902039
Collaborator
Chinese Academy of Sciences (Other)
100
1
60
1.7

Study Details

Study Description

Brief Summary

Diffusion prepared pseudo-continuous ASL (DP-pCASL) is a newly proposed MRI method to noninvasively measure the function of blood-brain barrier (BBB). The investigators aim to investigate whether the water exchange rate across the BBB, estimated with DP-pCASL, is changed in patients with CADASIL, and to analyze the association between BBB water exchange rate and MRI/clinical features in these patients.

Condition or Disease Intervention/Treatment Phase
  • Other: MRI

Detailed Description

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), caused by NOTCH3 gene mutations, is the most frequent monogenic type of hereditary cerebral small vessel disease (CSVD). The unique pathophysiological mechanisms that small vessel disorders in CADASIL are caused by genetic mutations and that the majority of patients do not combine cerebrovascular disease risk factors make CADASIL an ideal model for studying CSVD, and the imaging findings on CADASIL can be used to diagnose and investigate the etiology of CSVD. While abnormalities in the cerebrovascular structure and hemodynamics have been well demonstrated in CADASIL, the abnormality of the BBB remains controversial. One DCE-MRI study suggested an increase in BBB permeability to gadolinium contrast in CADASIL, whereas no abnormality of BBB was found in subsequent studies in mouse models and patients. The aim of this study was to assess whether BBB function is abnormal in patients with CADASIL using DP-pCASL, which is more sensitive to subtle changes in the BBB compared to DCE-MRI. The investigators hypothesized that the BBB water exchange rate (kw) is reduced in patients with CADASIL compared to controls as assessed by DP-pCASL and that the degree of reduction in BBB water exchange rate correlates with the severity of disease in patients with CADASIL.

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Case-Control
Time Perspective:
Cross-Sectional
Official Title:
MRI Study of Blood-brain Barrier Function in CADASIL
Actual Study Start Date :
Apr 1, 2021
Anticipated Primary Completion Date :
Apr 1, 2025
Anticipated Study Completion Date :
Apr 1, 2026

Arms and Interventions

Arm Intervention/Treatment
CADASIL patients

Inclusion Criteria: Patients with CADASIL confirmed by gene or/and skin biopsy. The age range is 20-70 years old. There is no contraindication to MRI examination, and the informed consent is signed. exclusion criteria: Combined with definite cerebrovascular disease, or combined with brain tumor, brain trauma and other causes of brain diseases. CADASIL is not confirmed. There are contraindications to examination or refusal to sign the informed consent.

Other: MRI
All participants underwent an MR examination on a 3T whole-body Prisma MRI system (Siemens, Erlangen, Germany) with a 64-channel head coil, and a 7T whole-body MAGNETOM MR system (Siemens, Erlangen, Germany) using a 32-channel receive/birdcage transmit head coil (NOVA medical). DP-pCASL, Multi-delay pCASL (MD-pCASL) was acquired to evaluate BBB function and cerebral perfusion. T1-weighted magnetization-prepared rapid gradient echo (T1w-MPRAGE) was scanned at both 3T and 7T for registration in the post-processing workflow. T2-weighted fluid-attenuated inversion recovery (T2w-FLAIR) and T2*-weighted gradient echo (T2*w-GRE) were acquired at 7T for high-resolution structural images and evaluation of lesions.
Other Names:
  • Cognitive Scale and Clinical Scale Evaluation
  • Healthy controls

    Inclusion Criteria: The age range is 20-70 years old. There is no contraindication to MRI examination, and the informed consent is signed. exclusion criteria: Combined with definite cerebrovascular disease, or combined with brain tumor, brain trauma and other causes of brain diseases. There are contraindications to examination or refusal to sign the informed consent.

    Outcome Measures

    Primary Outcome Measures

    1. kw [30 Minutes]

      Post-processing of DP-pCASL data was performed offline using LOFT BBB Toolbox. Head motion was corrected using SPM12 and the temporal fluctuations were minimized by using principal component analysis. DP-pCASL data with the b value of 50 s/mm2 were used to obtain the ASL signal from the tissue and capillary compartments respectively, and kw was quantified by using a single-pass approximation model with total generalized variation regularization.

    Secondary Outcome Measures

    1. CBF [30 Minutes]

      Post-processing of MD-pCASL data was performed offline using the BASIL toolkit of FSL. Cerebral blood flow (CBF) were calculated by a custom script using the BASIL toolkit of FSL.

    2. ATT [30 Minutes]

      Post-processing of MD-pCASL data was performed offline using the BASIL toolkit of FSL. Arterial transit time (ATT) were calculated by a custom script using the BASIL toolkit of FSL.

    3. QSM [30 Minutes]

      QSM image reconstruction, including phase pre-processing and estimation of susceptibility maps, followed the default QSMbox (https:// gitlab. com/ acostaj/ QSMbox) pipeline for single-echo, coil-combined data.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    1. Patients with CADASIL confirmed by gene or/and skin biopsy.

    2. The age range is 20-70 years old.

    3. There is no contraindication to MRI examination, and the informed consent is signed.

    Exclusion Criteria:
    1. Combined with definite cerebrovascular disease, or combined with brain tumor, brain trauma and other causes of brain diseases.

    2. CADASIL is not confirmed.

    3. There are contraindications to examination or refusal to sign the informed consent.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Peking University First Hospital Beijing China

    Sponsors and Collaborators

    • Peking University First Hospital
    • Chinese Academy of Sciences

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Peking University First Hospital
    ClinicalTrials.gov Identifier:
    NCT05902039
    Other Study ID Numbers:
    • 2022-715
    First Posted:
    Jun 13, 2023
    Last Update Posted:
    Jun 13, 2023
    Last Verified:
    Jun 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 13, 2023